The Journal of Precision Medicine

About adminpmls2016

This author has not yet filled in any details.
So far adminpmls2016 has created 49 blog entries.

Bristol Myers Squibb Reports First Quarter Financial Results for 2021

2021-04-29T12:00:12-05:00April 29th, 2021|

Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021, which reflect continued sales growth and advancement of the company’s product pipeline across our four core therapeutic areas.“We continue to deliver solid growth, execute against our strategic priorities and make meaningful progress across our pipeline,” said Giovanni Caforio, M.D., board chair and [...]

Mission Bio Announces Yan Zhang as New CEO

2021-04-09T09:21:40-05:00April 9th, 2021|

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role of CEO. Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she drove above-market growth for multiple business lines, including leading the commercial organization in China for Genetic Sciences and [...]

Diagnostic Laboratory Services, Inc. (DLS) Launches New Precision Medicine Program with GenomOncology’s Pathology Workbench

2021-04-09T09:18:18-05:00April 9th, 2021|

GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology (GO) Pathology Workbench to streamline variant analysis for their next generation sequencing (NGS) in support of the Queen's Medical Center's precision medicine program. DLS, an affiliate of the Queen's Health Systems, is the largest, locally-owned clinical laboratory in Hawaii. Historically, [...]

Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers

2021-04-09T09:08:23-05:00April 9th, 2021|

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed. The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and [...]

Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

2021-04-09T09:02:47-05:00April 9th, 2021|

Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests. The acquisition would bring Genosity's specialized capabilities onto the Invitae platform to accelerate [...]

Magellan Rx Management and Trapelo Health to Offer Precision Oncology Platform for Next-Generation Care

2021-04-09T08:58:24-05:00April 9th, 2021|

PHOENIX and BURLINGTON, MA (April 8, 2021): Magellan Rx Management, a division of Magellan Health, Inc. (NASDAQ: MGLN), and Trapelo Health, today announced that they are collaborating to champion a more comprehensive, integrated approach to value-based care in the new era of precision oncology treatments. The collaboration combines the unique strengths of the two [...]

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

2021-04-01T15:24:10-05:00April 1st, 2021|

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after [...]

Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial ahead of Planned Commercial Test

2021-04-01T15:20:10-05:00April 1st, 2021|

Delfi Diagnostics, Inc., a pioneering developer of next generation high performance, affordable liquid biopsy tests for early cancer detection, announced the start of enrollment for a nationwide prospective study and plans to commercialize an initial test in lung cancer before expanding into other cancer types. The Delfi lung cancer screening test, which combines advanced [...]

SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform

2021-04-01T15:16:55-05:00April 1st, 2021|

SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial intelligence and machine learning, and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have [...]

Genome Medical Expands Board of Directors and Leadership Team as Demand for Genomics Telehealth Services Grows

2021-04-01T15:13:13-05:00April 1st, 2021|

 Genome Medical, a digital health company bringing genetics and genomics into everyday care, today announced the appointment of Russell Glass, CEO of on-demand mental health company Ginger, to its Board of Directors as an independent director. In addition, to help guide the company's ongoing rapid growth, Genome Medical has appointed two key leaders to its [...]

Go to Top